Cristina Bugés

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway

Vicenç Ruiz de Porras, Sara Bystrup, Anna Martínez‐Cardús et al. · Scientific Reports · 2016 · 136 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

Cristina Santos, Daniel Azuara, J.M. Viéitez et al. · Annals of Oncology · 2019 · 29 citations · Full text

Medicine, Molecular Medicine, Oncology +17

EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.

Rafael Rosell, Miguel Ángel Molina‐Vila, Miquel Tarón et al. · Journal of Clinical Oncology · 2012 · 28 citations

Medicine, Oncology, Pharmacology +12

Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients

Vicenç Ruiz de Porras, Sara Bystrup, Sara Cabrero-de las Heras et al. · Cancers · 2019 · 20 citations · Full text

Medicine, Cancer Biology, Oncology +17

Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

Carmen Balañá, David López, Ramón De La Peñas et al. · Clinical & Translational Oncology · 2013 · 17 citations

Medicine, Oncology, Pharmacoeconomics +16